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Protocol
AbstrACt
Introduction Worldwide, millions of individuals are 
affected by neglected tropical diseases (NTDs). They are 
frequently the poorest and most marginalised members of 
society. Their living conditions, among other things, make 
them susceptible to such diseases. Historically, several 
large-scale treatment programmes providing mass drug 
administrations (MDAs) were carried out per single disease 
but over the last decade there has been an increasing 
trend towards co-implementation of MDA activities given 
the resources used for such programmes are often the 
same. The COUNTDOWN multicountry studies focus on 
scaled-up implementation of integrated control strategies 
against four diseases: lymphatic filariasis, onchocerciasis, 
schistosomiasis and soil-transmitted helminthiasis. The 
objective of the COUNTDOWN economic study is to assess 
the multicountry implementation of control interventions in 
terms of equity, impact and efficiency.
Methods The health economic study uses different 
analytical methods to assess the relationship between 
NTDs and poverty and the cost-effectiveness of different 
large-scale intervention options. Regression analysis will 
be used to study the determinants of NTD occurrence, 
the impact of NTDs on poverty, factors that hinder 
access to MDAs and the effect of NTDs on quality-
of-life of those affected, including disability. Cost-
effectiveness analyses of various integration methods 
will be performed using health economic modelling to 
estimate the cost and programme impact of different 
integration options. Here, cost-effectiveness ratios will 
be calculated, including multivariate sensitivity analyses, 
using Bayesian analysis.
Ethics and dissemination Ethics approval has been 
received both at the Liverpool School of Tropical Medicine 
and in all participating countries. Results of the various 
substudies will be presented for publication in peer-
reviewed journals.
study dates 1 July 2016 to 30 June-October 2019.
IntroduCtIon 
Neglected tropical diseases (NTDs) impact 
the lives of over 1 billion people in low-in-
come and middle-income countries.1 An 
estimated 5.9 million years of healthy life 
were lost in Sub-Saharan Africa (SSA) due to 
schistosomiasis (SCH), onchocerciasis (OV), 
lymphatic filariasis (LF) and soil-transmitted 
helminthiasis (STH) in 2013.2 About 90% of 
the global NTD disease burden is attributable 
to 7 of the 17 NTDs: these are SCH, OV, the 
strengths and limitations of this study
 ► This study will enable us to study the relationship 
between poverty and neglected tropical diseases 
(NTDs) from different angles: poverty distribution of 
NTDs, impact of NTDs on households, the access 
and adherence of households to mass drug adminis-
trations (MDAs) and the cost and cost-effectiveness 
of (MDAs).
 ► Secondary outcomes can allow us to assess often 
not considered (direct and indirect) impacts of NTDs 
including its effect on labour market participation 
and on schooling.
 ► A main limitation is with the duration of the study. 
To fully observe the poverty impact of NTDs and the 
role MDAs play, a longer period of study will be ap-
propriate, preferably beyond 2 years. This is, howev-
er, a first step in the right direction.
 ► The short period of time (maximum of 2 years for 
most interventions) limits the ability to fully appre-
ciate the impact of the different interventions on 
several socioeconomic variables such as education, 
labour market participation, incomes and adulthood 
outcomes.
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three STHs (roundworm, whipworm and hookworm), 
Trachoma and LF.3 
Since Grossman’s 1972 influential work on the demand 
for health, studies on the impact of health status on 
economic conditions have greatly increased.4 5 The focus 
has mainly been placed on HIV-AIDS, malaria and tuber-
culosis.6–8 The impact of NTDs on families, communities 
and economies, though under-researched, is considered 
to be immense.9 This may lead to school absenteeism, 
poor performance in school and a loss of productivity, 
including the inability to undertake agricultural work 
with consequent impact on food security and nutri-
tional quality.1 3 10 11 These effects, together with a reduc-
tion in the individual’s quality of life (QoL), can cause 
psychological problems and an increase in the demand 
for healthcare which may result in catastrophic health 
expenditures.1 3 10–12 The few studies that exist find signif-
icant effects on families and communities.13 For example, 
studies have shown that LF leads to an annual produc-
tivity loss of about US$1 billion in India.14 STH or SCH 
infection during childhood may have negative long-term 
effects on cognition and memory.10 15 16
NTDs affect the poorest and most marginalised individ-
uals and households, for whom neither prevention nor 
treatment is accessible.13 17 They disproportionately affect 
individuals whose living and working conditions make 
them especially vulnerable.18–20 Generally, lack of access 
to health services makes it difficult to diagnose and treat 
such infections early. Thus, not only may NTDs lead to 
poverty, they may also be caused by it. The vicious cycle 
of NTDs and poverty needs to be better understood. The 
relatively low global burden assigned to these diseases, 
however, means that they are often not high on the 
agenda of relevant stakeholders.21–24
Various NTDs, including LF, OV, SCH and STH, have 
cost-effective prevention and treatment options.21 These 
are often administered annually via national mass drug 
administration (MDA) or mass administration of medi-
cines (MAM) programmes.21 For example, OV and LF 
are often controlled using the donated drug ivermectin 
(IVM), at a cost of between US$14 and US$3030 per 
disability-adjusted life-year (DALY) averted.21 25 These 
costs arise mostly from the distribution of the medication, 
training community distributors, supervision and moni-
toring and evaluation.25
In-country MDA programmes may come at substantial 
cost. They involve the use of both health and educational 
facilities and employees including teachers. This involves 
both time and direct monetary costs.26–29 A recent study 
estimates that the total societal and household benefits 
obtained by achieving the 2020 London Declaration NTD 
targets for LF, OV, SCH, STH and trachoma is US$27.4 for 
each dollar spent for the period 2015–2020 with a return 
of US$42.8 for the 2021–2030 period.9 The declaration 
focuses on the elimination of LF and blinding trachoma 
and the control of OV, SCH and STH by 2020.30
In the case of high co-endemicity and comorbidity, the 
issue of integrated preventive chemotherapy (PC), as 
opposed to vertical PC, becomes particularly attractive. 
From the health system perspective, integrating NTD 
control programmes is a means of using resources more 
effectively and building more responsive processes.31–33 
This could lead to increases in coverage rates, an essential 
prerequisite for all NTD elimination policies.34 A recent 
study found that using the integrated PC programme for 
treating trachoma, SCH, STH and LF in six districts in 
Niger saved 16% in programme costs for 2008 and 21% 
in 2009.34
Reaching the 2020 targets will be beneficial to both 
individuals and other stakeholders9 and will contribute to 
the fight against poverty.35 However, current drug admin-
istration campaigns are limited in the extent to which 
they integrate with broader efforts to address diseases 
and build stronger health systems. In addition, studies on 
the economic effects of these programmes are rare and in 
cases where they exist tend to focus on cost-effectiveness 
analysis (CEA) and on single diseases, rather than taking a 
broader health systems approach. Hard-to-reach groups, 
as well as equity impact, have rarely been included. There-
fore, detailed assessments of the cost, cost-effectiveness 
and societal impact of expanded access to treatment of 
all population groups are urgently needed.
The main objectives of the COUNTDOWN project 
are to study the most effective, cost-effective, sustain-
able and acceptable current and complementary strate-
gies to implement scaled-up NTD treatments in Ghana, 
Cameroon, Liberia and Nigeria. This should lead 
to meeting the 2020 London Declaration goals and 
strengthen in-country health systems. This present study 
aims to identify generalisable factors which influence the 
acceptance, effectiveness, efficiency and equity impact of 
scale-up from a health systems approach. It also explores 
the most effective strategies to work with community 
drug distributors (CDDs) and community health workers 
(CHWs) to extend the scaling up of MDA to include 
hard-to-reach communities and build the resilience of 
vulnerable and marginalised groups. The project will 
study the various ways of integrating NTD programmes 
to strengthen health systems, foster cross-sector working 
(eg, sanitation, water resources and agriculture) to 
deliver a sustainable impact in support of NTD affected 
populations.
More specifically, the health economics component of 
the project has three main substudies. Substudy 1 aims 
to analyse the economic burden of NTDs at the house-
hold level by means of household surveys, at baseline and 
(selective) postimplementation of NTD efforts. Substudy 
2 aims to study the value for money of the investment in 
COUNTDOWN interventions from a societal perspec-
tive. These interventions include expanded community 
treatment of SCH and STH in Ghana and Cameroon and 
a treatment of OV with doxycycline (and ground larvi-
ciding) in Cameroon. Costing surveys will be carried 
out and used together with data from the household 
survey, existing economic models and reference prices. 
Substudy 3 will estimate the budgetary impacts of the 
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COUNTDOWN interventions and identify opportunities 
for affordable scale-up and integrated implementation at 
the national, district and community level.
MEthods And dEsIgn
substudy 1: analyse the economic burden of ntds, using 
secondary data and carrying out household level surveys, at 
baseline and (selective) postimplementation of ntd effort
The goal is to analyse issues around NTD-related health 
inequalities. The focus will be on the bidirectional rela-
tionship between health and poverty as well as the effect 
of NTDs on disability. We will look at (1) the socioeco-
nomic determinants of NTD community prevalence, (2) 
the relationship between poverty and NTDs, (3) issues of 
accessibility and adherence to MDAs and (4) the relation-
ship between NTDs and disability. This substudy will be 
carried out in Ghana, Cameroon and Liberia.
The socioeconomic determinants of NTD community prevalence
Setting
Nationally representative data will be used, namely, the 
sixth Ghana Living Standards Survey (GLSS6) collected in 
2012/2013, the fourth Cameroonian Household Survey 
(ECAM 4) collected in 2014 and the Liberian Household 
Income and Expenditure Survey (LHIES) collected in 
2014/2015.36–38
The goal of the GLSS6, which was initiated by the 
World Bank in 1980, is to collect information on house-
hold consumption and expenditure, health-related infor-
mation, education and community level using various 
survey instruments.36 The GLSS6 data collection took 
place from 18 October 2012 to 17 October 2013.
The ECAM collected information in 2014, which 
included expenses and acquisition of household goods, 
demography, individual time use, education, health and 
income of household members.
The goal of the LHIES was to collect household level 
information on education, health, employment, water 
and sanitation, expenditures, household resources 
among others.39 The survey used a two-stage sampling 
methodology. Data collection was over a 1-year period 
from 1 January 2014 to 1 January 2015.37
Data analysis
We will use community-level prevalence estimates from 
the national NTD programmes in various countries and 
from an extensive grey literature review for the years 
before the socioeconomic data were collected. To study 
the socioeconomic and demographic determinants of 
community NTD prevalence, we will run separate ordi-
nary least squares (OLS) regressions for each NTD in 
question. We will also run a multivariate OLS model to 
account for possible co-endemicity. There is a likelihood 
of reverse causality between the measures of household 
wealth and NTD prevalence.
While poverty might lead to NTD infections, having a 
high NTD prevalence might also lead to poverty. We will 
therefore need to control for potential biases. We will 
employ the instrumental variables approach, provided a 
good instrument is found for endogenous variables. An 
instrument is defined as any variable that (1) is correlated 
with the endogenous variable, but not with the depen-
dent variable and (2) is uncorrelated with the error term 
of the main equation.40 Appropriate instruments will be 
used where feasible.
The relationship between poverty and NTDs, and disability and 
NTDs
Setting, sampling strategy and sample size
The COUNTDOWN consortium will develop a survey to 
collect household level data on sociodemographic char-
acteristics, education, general health, health spending, 
disability (adapting the DHS disability questions and 
the EQ-5D) and MDA access in selected communities 
in Ghana, Cameroon and Liberia. The COUNTDOWN 
interventions will also involve the direct testing of house-
hold members for diseases. With these parasitological 
and socioeconomic data, we will study the impact of 
the NTDs on household incomes, schooling and labour 
market participation in the selected community. We will 
also analyse the socioeconomic factors that make individ-
uals in these communities vulnerable to NTDs and their 
access to the national MDA programmes.
In order to study the direct impact of NTDs on house-
holds, we will need to be able to match individuals affected 
by NTDs to others not infected by the respective diseases. 
The COUNTDOWN project will conduct diagnostic 
tests for different NTD infections at the household level 
in Ghana (SCH and STH) and Cameroon (OV). These 
diagnostics will therefore enable such analyses. The study 
sites for this work will include sites from the two interven-
tion strategies described in substudy 2. Figure 1 gives a 
summary of the sampling strategy for the baseline survey 
in relation to the COUNTDOWN interventions.
We will select cases with NTD infections with a match 
to controls (individuals) based on age and gender. For 
each selected case, two controls (individuals who are 
not infected by the NTD under study) will be assigned. 
To determine the required sample of cases needed for 
the analysis, we will use the methodology of tests for 
two correlated proportions in a matched case–control 
design41 such that if we assume that the intervention will 
improve the rate of primary endpoint from 5% to 10% 
(OR of 2) and 0.2 of the correlation coefficient for the 
primary endpoint, 630 cases (1260 controls) will provide 
90% power at a 0.05 significance level. We will add 25 extra 
cases to account for non-response and attrition, implying 
a total sample size of 655 cases and 1310 controls. These 
sample sizes will be revised if needed, based on the final 
diagnostic results.
Data analysis
Poverty distribution of NTDs
To study the poverty distribution of households in 
communities with high NTD prevalence and compare 
 o
n
 17 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020113 on 30 June 2018. Downloaded from 
4 Woode ME, et al. BMJ Open 2018;8:e020113. doi:10.1136/bmjopen-2017-020113
Open access 
this with other communities, we will rank households 
based on a poverty measure. We will use three measure-
ments of poverty, namely, household consumption expen-
diture, household income and an asset index (AI). We 
will provide the standard measures of poverty in terms 
of expenditure and incomes. However, given that data of 
this type are often collected retrospectively and, in some 
cases, individuals are unwilling to provide such informa-
tion, the quality of data collected is often low.
The AI relies less on recall as it will be created from a 
list of assets owned by the household. AIs are often used 
as relative measures of poverty, especially if income data is 
of poor quality.42 Principal component analysis (PCA) will 
be used22 to classify the households into five asset quin-
tiles. We will use Student’s t-tests to compare AIs between 
the districts, in general, and the subdistricts with high 
NTD prevalence. The proportion of households with and 
without NTDs in the two poorest asset quintiles (first and 
second) will be considered as a measurement of poverty.43 
It is expected that higher proportions of households in 
the poorest quintiles will be infected with NTDs.
 
NTDs and catastrophic health spending
Using total household consumption expenditure and 
household health expenditure (out of pocket (OOP) 
spending) for NTDs, we will measure the incidence of 
catastrophic health expenditure (CHE). Households 
that will incur NTD-related health expenditure corre-
sponding to 10% or more of total household consumption 
expenditure or 40% of total household non-food expen-
diture will be classified as facing CHE.44
Incidence of CHE in households with and without 
NTDs will be calculated for assessing the impact of NTDS 
on CHE incidences. The determining factors of CHE 
will then be studied using a logistic regression. Further, 
to estimate the poverty impact, we will calculate what 
proportions of households fall below the poverty line 
(daily expenditure of US$1.90 per person45) by calcu-
lating total household expenditure with and without 
household health expenditure for NTDs.
 
The effect of NTDs on poverty
To study the possible effect of NTDs on poverty, 
concentration indices will be estimated using the AI. 
These indices are used to measure the degree of socio-
economic-related inequality in health sector variables. In 
our case, the relevant variable is NTD infection. Multi-
nomial, biprobit and nested logit regression analyses will 
be carried out to test whether NTD infections influence 
wealth, education and labour market participation.46 We 
will test and control for potential endogeneity using the 
instrumental variables approach where appropriate.
 
The relationship between NTDs and disability
A descriptive analysis will be carried out to examine the 
disability status of individuals infected with NTDs. We will 
estimate a logistic regression and a bivariate probit model 
to examine the impact of NTDs on disability.
Figure 1 Sampling strategy for baseline survey.
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Inclusion, exclusion and eligibility
All individuals from selected households in Ghana and 
Cameroon who provided written informed consent to be 
interviewed and to give samples to be tested for NTDs will 
be included in the study. We will exclude individuals and 
households who did not give consent to be interviewed 
and to provide samples.
Individuals of the same gender and age as a case (up to 
two such individuals per case) who had provided written 
informed consent to give samples and were tested to 
have not had any of the NTDs being studied as part of 
the COUNTDOWN project and their consenting house-
hold members will be included. Individuals unable to give 
consent and all individuals who were tested to be NTD 
negative, but withdrew consent will be excluded.
Accessibility and adherence to national MDA programmes
Setting, sampling strategy and sample size
We will use community-level prevalence estimates from 
the national NTD programmes in various countries and 
from an extensive grey literature review. To study access 
and adherence to national MDA programmes and to the 
COUNTDOWN interventions, we will collect primary 
data on household characteristics, access and adherence 
using a household questionnaire. Following Offei and 
Anto,47 we will divide the communities into rural and 
urban areas. From each group, we will randomly select 
communities. Households will be randomly selected from 
each community using a random list of households gener-
ated from the total number of households in the district, 
where each household will be given a unique identifica-
tion number.
We calculate the required sample size using the 
formula47:
  
n =
p´
(
1−p´)(Zα
2
)2
(
d
)2
  (1)
where we fix our desired statistical significance level at 
5% ( Z
α
2  = 1.96). If we assume an average national MDA 
coverage of 85%  
(
p´ = 0.85
)
  and a 5%  
(
d = 0.05
)
  precision, 
we will need a sample size of 195 households split propor-
tionally across the selected communities. To account for 
non-responses we will include an extra 10%, bringing 
the total number of households to 214. We will interview 
the head of each household or the most knowledgeable 
person in the household. The head of the household is 
defined as the person who makes the decisions or has the 
final say within the household. For the individual-specific 
questions, consenting individuals (or a parent or guardian 
for individuals below the age of 15) will be interviewed.
Data analysis
The analysis will begin with a descriptive study of accessi-
bility and adherence based on individual, household and 
community characteristics including information on the 
CDDs. This will be followed by an empirical analysis using 
both the nested and sequential logit models.
Though we can analyse access and adherence sepa-
rately, it is important to recognise the possible correla-
tions between the two. It is possible that individuals who 
do not have access to treatment and those who do not 
adhere are similar. In addition, the question of adher-
ence only comes into play after gaining access to MDAs, 
and thus our data is of the nested/sequential form. We 
will use the Heckman two-step model to correct for any 
selection bias.
Inclusion, exclusion and eligibility
All individuals from selected households in Liberia, 
Ghana and Cameroon who provided written informed 
consent to be interviewed and to give samples to be tested 
for NTDs will be included in the study. We will exclude 
individuals and households who did not give consent to 
be interviewed and to provide samples. Individuals unable 
to give consent and all individuals who were tested to be 
NTD negative, but withdrew consent will be excluded.
substudy 2: cost-effectiveness analyses of countdown 
interventions
The goal is to assess whether each of the interventions is 
good value for money.48
Setting
The COUNTDOWN project aims to implement several 
interventions for three NTDs. An extended MDA inter-
vention for SCH and STH and a treatment with doxy-
cycline together with specific vector control measures 
(using larviciding) for OV. The extended MDA inter-
vention for SCH and STH will be carried out in Ghana 
and Cameroon. It involves the provision of praziquantel 
(PZQ) and mebendazole (MBD) (or albendazole, ALB, 
for Ghana) to the whole community. The current treat-
ment in both countries are school based. Treatment will 
take place at time period 0 months and 12 months with 
parasitological tests taking place at time 0 months, 6 
months, 12 months and 18 months.
For the OV study in South Western Cameroon, 10 of the 
20 selected communities will receive doxycycline without 
ground larviciding, while the other 10 will receive doxy-
cycline with ground larviciding. Doxycycline will only be 
offered to the individuals who have tested positive for OV. 
Doxycyline treatment is over a 5-week period where indi-
viduals take a dose each day during this 5-week period.
These interventions are presented in figure 2. The 
sample for our study will be individuals in these interven-
tion studies.49 Both interventions will be carried out over 
an 18-month period. The medicines will be provided to 
everyone in the selected community and they are free to 
take part in the intervention or decline. A full description 
of the SCH/STH intervention in Ghana can be found 
in Campbell et al50 and the full protocols for the work in 
Cameroon are available on request.
Data analyses
We will compare the proposed interventions to the 
already existing intervention of one MDA annually. CEA 
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in low-income and middle-income countries is often diffi-
cult due to a lack of (accurate) costing data.51 We will use 
market values and proxies to overcome some of these 
challenges in obtaining cost estimates. In our study, we will 
use direct observation methods such as time and motion 
techniques, activity logs, participant recorded activity logs 
and patient diaries as well as participant-based methods 
such as self-reported activity logs and direct assessment 
during the interventions.48 Household-specific cost infor-
mation will also be collected.
We will adopt the societal perspective for this study. 
This, in general, implies that (1) there is an inclusion 
of all productivity gains and losses, (2) the cost of drugs 
and other inputs will be measured using opportunity 
costs and (3) health state utilities are estimated using of 
community preferences.52 53 The costs will be the loss of 
non-health related welfare due to the use of resources for 
health provision, while the benefits will relate to the gains 
in welfare due to an improvement in health.54
Cost analysis
The COUNTDOWN interventions involve different types 
of costs including the patient-specific costs, the health 
system costs, the cost of primary healthcare workers 
including CDDs and the education system costs for 
school-based interventions. Patient-specific costs include 
productivity losses (absenteeism, presenteeism, loss of 
schooling time, etc), transportation costs and other costs 
(both direct and indirect) incurred by the patient when 
they take part in the intervention.
To estimate the total costs, we will use a retrospective 
micro-costing methodology. The main cost dimensions 
include programme-specific expenditure, the opportu-
nity costs or value of governmental contributions related 
to in-kind costs of using local government staff and vehi-
cles and the value of CDD’s time, the international costs 
of programme coordination, reporting and technical 
support.27–29 55
A comprehensive list of resources consumed in the 
provision of the different interventions will be created 
using direct observation of the intervention process and 
via interviews with clinical personnel, consultations with 
experts and activity-based costing.56 The general list of 
costing will fall under health service use, productivity 
loss, informal carers, transportation and other non-health 
service costs. These are presented in table 1. We will use 
a discounting rate of 3% adjusting further for inflation.57 
All cash expenditures paid for the implementation of the 
intervention will be estimated.27–29 55
Effectiveness: programme evaluation
In measuring the effectiveness of NTD control through 
MDAs, several studies have used varying indicators. These 
range from infection cases averted to DALYs.26 28 29 58 We 
will use infection cases averted as measured by change in 
infection occurrence as our main effectiveness measure. 
Other indicators include measures of disease intensity 
(from the stool, urine, blood and skin snip samples) and 
other morbidity indicators such as anaemia for SCH, 
lymphangio-adenitis for LF and skin nodules for OV. The 
Figure 2 Concept map for health economics evaluations alongside the COUNTDOWN interventions. DALY, disability adjusted 
life year; ICER, incremental cost-effectiveness ratio; MDA, mass drug administration; NTD, neglected tropical disease; QALY, 
quality adjusted life year; QoL, quality of life. 
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OV parasitology will enable us have follow-up informa-
tion for the same individuals, while the SCH and STH 
parasitology will be a repeated cross-section at 6 months 
interval. We will also check for MDA coverage (both 
for COUNTDOWN interventions and National MDA 
programmes).
Cost-effectiveness analyses
We will measure cost-effectiveness using the incremental 
cost-effectiveness ratio (ICER) against the baseline situation.
Sensitivity analyses
Sensitivity analyses will be carried out to find out the 
effect of a change in some key variables on the cost-effec-
tiveness of the interventions. We will start with univariate 
analyses and then proceed to multivariate analysis using 
regression. Tornado graphs will be produced to show 
the changes in ICER as a result of changes in parameter 
values. In the multivariate analysis, more than one vari-
able will be allowed to vary in the regressions.
We will also carry out probabilistic sensitivity 
analyses through the use of Monte-Carlo simula-
tions. Cost-effectiveness acceptability curves will be 
produced using non-parametric bootstrap techniques. 
For comparability, parametric techniques will also be 
applied using the Fieller’s theorem method.59 This 
method calculates CIs for ratios with the assumption 
that both the numerator and the denominator follow 
a bivariate (log-) normal distribution. The distribu-
tion of the cost-effectiveness ratio is not required to 
be either normal or symmetric. Bayesian techniques 
will be adopted where appropriate.
Outcomes
Primary outcomes
 ► Direct costs: drugs, staff time, equipment, transport, 
OOP.60
 ► Indirect costs: production losses, other uses of time 
including schooling and leisure.
 ► Intangibles: pain and suffering, adverse effects from 
medicines.
 ► Incremental cost-effectiveness ratio.
Secondary outcomes
 ► Disease occurrence.
 ► Severity.
 ► Morbidity.
Table 1 Costing dimensions
Costing element Measurement Items
Health service Cost of intervention through direct 
observations, interviews of clinical 
personnel, consultations with experts and 
activity based costing.
Personnel, equipment, pharmaceuticals, overhead 
(including utilities), building costs, administrative costs 
(including printing, posting, rents, security, cleaning), 
furniture, diagnostics, disposables, computer hardware 
and software, accommodation, per diems, training, 
supervision, travel allowances, health clinic staff costs 
for community drug distributor (CDD) selection (per 
diems and fuel).
Primary health workers Cost of intervention through direct 
observations, field diaries and activity 
based costing.
Cost of using CDDs and other community health 
workers.
Education service Cost of training teachers, cost of 
education services used during 
programme implementation
Teachers costs, cost of teacher’s time, per diems, 
teacher training, supervision, etc.
Productivity loss Missed work, schooling and absenteeism 
over the last 4 weeks attributable 
to neglected tropical disease under 
study obtained using patient-specific 
questionnaires.
Presenteeism, missed work, missed school, missed 
unpaid work time per affected day, time needed to 
catch-up with missed unpaid work.
Informal carers Opportunity costs for time spent by 
other household members to care for 
younger children and ill household 
members obtained using patient-specific 
questionnaires.
Time spent caring for other household members while 
individual goes to seek treatment.
Transportation Obtained using patient-specific 
questionnaires.
Time spent going to centre for mass drug administration, 
cost of transport to destination.
Other non-health service 
costs
Obtained through direct observations, 
interviews of clinical personnel, 
consultations with experts, activity 
based costing and patient-specific 
questionnaires.
Cost of insecticides and larvicides.
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Inclusion, exclusion and eligibility
All individuals who consented to participate in the inter-
vention and to being interviewed for the cost-effective-
ness study will be included in the sample. Individuals 
and their households will be removed from the sample 
if they are, for whatever reason, unable to give consent to 
be interviewed or change their minds during the inter-
viewing process. Individuals and their households will be 
removed from the case–control study if they rescind their 
consent for the second interview at any time before the 
end of that second interview.
substudy 3: model-based analysis: macro-micro economic 
impact of ntd control
The goal of this substudy is to estimate the long-term 
impact and cost-effectiveness of NTD control using 
Markov time-dependent macro-micro simulation model 
and discrete event simulation (DES).61 We will look at 
the budgetary impact of wider implementation of NTD 
control. In addition, we will look at the cost-effective-
ness of integrating PC programmes studied as part of the 
COUNTDOWN project.
Setting
Using results from substudies 1 and 2, we will simulate the 
potential effects of the different COUNTDOWN interven-
tions on disease occurrence. We are interested in finding 
out how different integration strategies will perform in 
terms of disease control and elimination. We will model 
these effects over a 10-year period with projections of 
potential benefits and costs in monetary and non-mon-
etary terms.
Data analysis and outcomes
We will estimate the disease impact and cost-effectiveness 
of the different interventions over a specified period using 
inputs and results from previous cost-effectiveness studies. 
We will use a Markov model with external (intervention 
costs) and internal costing (health system costs). We will 
also use DES models to incorporate specific epidemiolog-
ical results.62 We will address parameter uncertainty using 
Monte-Carlo simulations and Bayesian analysis. Figure 3 
presents a basic description of the model. This figure is 
adapted from Drummond et al.63
Based on the data collected and the results obtained, 
we will test different integration strategies and the effects 
they will have on the disease. We will also examine the 
cost-effectiveness of the different strategies and their 
limitations.
Results will initially be presented at various conferences, 
seminars and workshops in the countries of study and 
internationally. Results will also be published in peer-re-
viewed journals. A summary of the results will be included 
in the final COUNTDOWN project report.
Patient and public involvement
Patients were not directly involved in the development of 
the health economics component of the COUNTDOWN 
project. NTD programme managers were consulted on 
the design of the work and are included in the list of 
involved COUNTDOWN members.
dIsCussIon
The goal of the proposed project is to study the economics 
of NTDs by focusing on the equity and effectiveness in the 
scaled-up implementation of integrated NTD control. 
The focus is on four disease groups, namely, SCH, STH, 
LF and OV. The health economics component will have 
three different objectives: (1) to analyse the economic 
burden of NTDs at the household level, by carrying out 
household level surveys, at baseline and (selective) post-
implementation of NTD effort, (2) to study the cost-ef-
fectiveness of the COUNTDOWN intervention and (3) to 
study the macro-micro economic impact of NTD control.
Figure 3 Economic decision model components. DALY, disability adjusted life year; HALY, healthy adjusted life years; LYG, life 
years gained; QALY, quality adjusted life year. 
 o
n
 17 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-020113 on 30 June 2018. Downloaded from 
9Woode ME, et al. BMJ Open 2018;8:e020113. doi:10.1136/bmjopen-2017-020113
Open access
In terms of limitations, there is the risk of individuals 
refusing to be tested for the diseases for various reasons 
at either the baseline or during the follow-up. Without a 
specific diagnosis, it will be difficult to study the impact 
of NTDs on the households and the risk factors as some 
individuals will be asymptomatic. The sample size will, in 
turn, be limited by our ability to carry out diagnostics.
This limitation aside, the proposed studies will offer 
valuable and unique insights on the costs, effectiveness 
and the equity impact of NTDS and their integrated 
control on the most vulnerable individuals living on the 
fringes of society. It will offer insights on the paths to be 
taken towards the elimination of these diseases and the 
benefits to be obtained by focusing on these diseases. 
It will provide significant economic evidence to health 
policymakers and implementation functionaries towards 
NTD control and help decision-makers to integrate 
further the prevention and treatment of such diseases 
and their control in current health systems.
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